A systematic review and meta-analysis of elevated lipoprotein(a) and adverse limb outcomes in peripheral artery disease after revascularization
Journal of Vascular Surgery · 2026
DOI: 10.1016/j.jvs.2026.05.016 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Vascular Surgery, 2026. Verfasst von Bibombe P Mwipatayi und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Surgery, University of Western Australia, Perth, WA, Australia. Electronic address: patrice@bibombe.com. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Lipoprotein(a), Lower Extremity, Vascular Surgical Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Future Fund, National Heart Foundation of Australia, National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVE: Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein with a well-established role in cardiovascular disease. However, its association with peripheral artery disease (PAD) prevalence and limb-related outcomes after lower-extremity revascularization remains incompletely defined. We conducted a systematic review and meta-analysis to evaluate the relationship between elevated Lp(a), PAD prevalence, and postrevascularization limb outcomes. METHODS: A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE, Embase, CINAHL, and Web of Science were searched from January 1990 through August 2024 to identify observational studies reporting associations between Lp(a) levels and the prevalence of PAD and/or outcomes after lower-extremity revascularization. Risk of bias was assessed using the Risk of Bias in Non-randomized Studies of Exposure tool and the Revised Cochrane Risk-of-Bias tool, and certainty of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation framework. Pooled odds ratios (ORs) and mean differences were estimated using random-effects models. Between-study heterogeneity was quantified using the I2 statistic; prespecified sensitivity and subgroup analyses were performed. RESULTS: Ten observational studies comprising 5794 participants met the inclusion criteria. Elevated Lp(a) was associated with a significantly greater prevalence of PAD (pooled OR, 1.81; 95% confidence interval [CI], 1.37-2.39; P < .001), with low heterogeneity (I2 = 26%). This association remained consistent in prospective cohort studies (OR, 1.60; 95% CI, 1.24-2.07; I2 = 0%). Patients with PAD also had higher circulating Lp(a) concentrations than control participants without PAD (mean difference, 21.8 mg/dL; 95% CI, -5.5 to 49.1), although heterogeneity was substantial (I2 = 85%). Among patients undergoing lower-extremity revascularization, only two observational cohort studies contributed to pooled limb-outcome analyses. Within this limited evidence base, elevated Lp(a) was strongly associated with adverse limb outcomes, including repeat target-lesion revascularization (OR, 3.22; 95% CI, 2.36-4.40), major adverse limb events (OR, 5.09; 95% CI, 3.89-6.67), and major amputation (OR, 2.62; 95% CI, 1.36-5.03), with no detectable heterogeneity across these end points (I2 = 0%). Several included studies reported estimates adjusted for established vascular risk factors, including diabetes mellitus, smoking, hypertension, and lipid-lowering therapy; however, harmonized adjusted estimates were not available for all pooled analyses. CONCLUSIONS: Elevated Lp(a) is consistently associated with increased PAD prevalence and adverse limb-related outcomes after lower-extremity revascularization. These findings better define Lp(a) as a marker of limb-related risk and postprocedural prognosis in patients with PAD. However, the current evidence remains insufficient to conclude that Lp(a)-directed treatment improves PAD-specific outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Surgery, University of Western Australia, Perth, WA, Australia. Electronic address: patrice@bibombe.com.
- Department of Vascular Surgery, Royal Perth Hospital, Perth, WA, Australia.
- Royal Perth Hospital Library, Royal Perth Hospital, Perth, WA, Australia.
- Department of Vascular Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Vascular Surgery and Endovascular Therapy, Center for Aortic Diseases, University of Chicago, Chicago, IL.
- Medical School, University of Western Australia, Perth, WA, Australia.
Förderung
- Medical Research Future Fund
- National Heart Foundation of Australia
- National Health and Medical Research Council
- Townsville Hospital and Health Service
Zitieren
APA
Mwipatayi, B. P., Dodd, J., Ahmad Bazlee, A. H., Jones, G., Verhagen, H. J. M., Milner, R., Mori, T. A., Watts, G. F., Golledge, J., & Schlaich, M. P. (2026). A systematic review and meta-analysis of elevated lipoprotein(a) and adverse limb outcomes in peripheral artery disease after revascularization. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2026.05.016
Vancouver
Mwipatayi BP, Dodd J, Ahmad Bazlee AH, Jones G, Verhagen HJM, Milner R, et al. A systematic review and meta-analysis of elevated lipoprotein(a) and adverse limb outcomes in peripheral artery disease after revascularization. Journal of Vascular Surgery. 2026. doi:10.1016/j.jvs.2026.05.016
BibTeX
@article{Mwipatayi2026,
author = {Mwipatayi, Bibombe P and Dodd, James and Ahmad Bazlee, Amirul H and Jones, Glynis and Verhagen, Hence J M and Milner, Ross and Mori, Trevor A and Watts, Gerald F and Golledge, Jonathan and Schlaich, Markus P},
title = {A systematic review and meta-analysis of elevated lipoprotein(a) and adverse limb outcomes in peripheral artery disease after revascularization},
journal = {Journal of Vascular Surgery},
year = {2026},
doi = {10.1016/j.jvs.2026.05.016}
}
EUVIMED